This study looked at amyloid precursor protein (APP) degradation
products in the CSF of MS patients at different stages of disease, in
addition to the effects of disease modifying therapy. CSF samples were
obtained from 87 MS patients, including 54 RRMS, 33 SPMS and 28
controls. They found that CSF APP and Aβ (Amyloid Beta) peptide levels
were reduced in MS patients, however they increased towards normal after
natalizumab therapy. This may be due to natalizumab counteracting the
altered APP metabolism in MS. The combined pattern of Aβ peptide allowed
them to distinguish between controls and SPMS patients.
study highlights the complexities of APP metabolism in
neuroinflammation. Further studies are needed to increase our
understanding of the role of APP metabolism in MS.
Authors: Augutis K, Axelsson M, Portelius E
Source: Mult Scler. 2012 Oct 15. [Epub ahead of print]
Read the abstract